{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T13:56:30Z","timestamp":1784382990787,"version":"3.55.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Hyperfunctional mitochondria provide a growth advantage by supporting the energy-intensive processes essential for non-small cell lung cancer (NSCLC). NADH:ubiquinone oxidoreductase core subunit S8 (NDUFS8) is a key subunit of mitochondrial complex I involved in oxidative phosphorylation (OXPHOS) and cellular energy production. Bioinformatics and local tissue examinations show that NDUFS8 expression is elevated in NSCLC compared to normal lung tissue. Both immortalized and primary human NSCLC cells exhibit higher NDUFS8 levels. Single-cell RNA sequencing confirmed NDUFS8 upregulation in cancerous cells of NSCLC tumor. Silencing NDUFS8 via shRNA or Cas9\/sgRNA-mediated knockout (KO) disrupted mitochondrial functions, leading to decreased complex I activity, ATP depletion, mitochondrial depolarization, increased reactive oxygen species (ROS) production, and heightened lipid peroxidation. Furthermore, NDUFS8 silencing\/KO triggered apoptosis and significantly reduced Akt-mTOR activation, cell viability, proliferation, and motility in various NSCLC cells. In contrast, ectopic overexpression of NDUFS8 boosted mitochondrial complex I activity and ATP levels, promoting Akt-mTOR activation, and enhancing NSCLC cell proliferation and motility. NDUFS8 also contributes to radioresistance in NSCLC; silencing or KO enhanced ionizing radiation (IR)-induced cytotoxicity, while overexpression mitigated it. Intratumoral injection of NDUFS8 shRNA-expressing adeno-associated virus significantly inhibited growth of primary NSCLC xenografts in nude mice, with observed NDUFS8 silencing, ATP reduction, oxidative damage, proliferation inhibition, Akt-mTOR inactivation and apoptosis in treated tissues. These findings highlight the pivotal pro-tumorigenic role of NDUFS8 in NSCLC.<\/jats:p>","DOI":"10.1038\/s41419-025-07638-5","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T03:39:13Z","timestamp":1745206753000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["NADH:ubiquinone oxidoreductase core subunit S8 expression and functional significance in non-small cell lung cancer"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3881-3106","authenticated-orcid":false,"given":"Weihua","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongpeng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianbao","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-zhao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubo","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3207-3429","authenticated-orcid":false,"given":"Mingjing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0298-0778","authenticated-orcid":false,"given":"Kanqiu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"key":"7638_CR1","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S2214-109X(19)30482-6","volume":"8","author":"M Arbyn","year":"2020","unstructured":"Arbyn M, Weiderpass E, Bruni L, de Sanjose S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob health. 2020;8:e191\u2013e203.","journal-title":"Lancet Glob health"},{"key":"7638_CR2","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(16)31340-X","volume":"388","author":"CT Hiley","year":"2016","unstructured":"Hiley CT, Le Quesne J, Santis G, Sharpe R, de Castro DG, Middleton G, et al. Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. Lancet. 2016;388:1002\u201311.","journal-title":"Lancet"},{"key":"7638_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","volume":"398","author":"AA Thai","year":"2021","unstructured":"Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398:535\u201354.","journal-title":"Lancet"},{"key":"7638_CR4","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jama.2019.11058","volume":"322","author":"KC Arbour","year":"2019","unstructured":"Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. Jama. 2019;322:764\u201374.","journal-title":"Jama"},{"key":"7638_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41419-017-0063-y","volume":"9","author":"TV Denisenko","year":"2018","unstructured":"Denisenko TV, Budkevich IN, Zhivotovsky B. Cell death-based treatment of lung adenocarcinoma. Cell Death Dis. 2018;9:117.","journal-title":"Cell Death Dis"},{"key":"7638_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1051\/bmdcn\/2017070423","volume":"7","author":"CY Huang","year":"2017","unstructured":"Huang CY, Ju DT, Chang CF, Muralidhar Reddy P, Velmurugan BK. A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer. BioMedicine. 2017;7:23.","journal-title":"BioMedicine"},{"key":"7638_CR7","doi-asserted-by":"crossref","unstructured":"Ghosh P, Vidal C, Dey S, Zhang L. Mitochondria targeting as an effective strategy for cancer therapy. Int J Mol Sci. 2020;21:3363.","DOI":"10.3390\/ijms21093363"},{"key":"7638_CR8","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ctrv.2013.08.006","volume":"40","author":"S Heavey","year":"2014","unstructured":"Heavey S, O\u2019Byrne KJ, Gately K. Strategies for co-targeting the PI3K\/AKT\/mTOR pathway in NSCLC. Cancer Treat Rev. 2014;40:445\u201356.","journal-title":"Cancer Treat Rev"},{"key":"7638_CR9","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553:446\u201354.","journal-title":"Nature"},{"key":"7638_CR10","first-page":"167","volume":"27","author":"S Jonna","year":"2019","unstructured":"Jonna S, Subramaniam DS. Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update. Discovery Med. 2019;27:167\u201370.","journal-title":"Discovery Med"},{"key":"7638_CR11","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1080\/0284186X.2017.1404634","volume":"57","author":"HH Vestergaard","year":"2018","unstructured":"Vestergaard HH, Christensen MR, Lassen UN. A systematic review of targeted agents for non-small cell lung cancer. Acta Oncol. 2018;57:176\u201386.","journal-title":"Acta Oncol"},{"key":"7638_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.canlet.2017.06.033","volume":"405","author":"X Meng","year":"2017","unstructured":"Meng X, Liu Y, Zhang J, Teng F, Xing L, Yu J. PD-1\/PD-L1 checkpoint blockades in non-small cell lung cancer: new development and challenges. Cancer Lett. 2017;405:29\u201337.","journal-title":"Cancer Lett"},{"key":"7638_CR13","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1634\/theoncologist.2019-IO-S1-s05","volume":"24","author":"L Xia","year":"2019","unstructured":"Xia L, Liu Y, Wang Y. PD-1\/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions. Oncologist. 2019;24:S31\u2013S41.","journal-title":"Oncologist"},{"key":"7638_CR14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1177\/107327481402100112","volume":"21","author":"BC Creelan","year":"2014","unstructured":"Creelan BC. Update on immune checkpoint inhibitors in lung cancer. Cancer Control. 2014;21:80\u201389.","journal-title":"Cancer Control"},{"key":"7638_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/cr.2017.155","volume":"28","author":"PE Porporato","year":"2018","unstructured":"Porporato PE, Filigheddu N, Bravo-San Pedro JM, Kroemer G, Galluzzi L. Mitochondrial metabolism and cancer. Cell Res. 2018;28:265\u201380.","journal-title":"Cell Res"},{"key":"7638_CR16","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.trecan.2017.10.006","volume":"3","author":"PJ Burke","year":"2017","unstructured":"Burke PJ. Mitochondria, bioenergetics and apoptosis in cancer. Trends Cancer. 2017;3:857\u201370.","journal-title":"Trends Cancer"},{"key":"7638_CR17","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.cell.2016.07.002","volume":"166","author":"S Vyas","year":"2016","unstructured":"Vyas S, Zaganjor E, Haigis MC. Mitochondria and cancer. Cell. 2016;166:555\u201366.","journal-title":"Cell"},{"key":"7638_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nchembio.1712","volume":"11","author":"SE Weinberg","year":"2015","unstructured":"Weinberg SE, Chandel NS. Targeting mitochondria metabolism for cancer therapy. Nature Chem Biol. 2015;11:9\u201315.","journal-title":"Nature Chem Biol"},{"key":"7638_CR19","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1158\/0008-5472.CAN-15-0491","volume":"75","author":"A Viale","year":"2015","unstructured":"Viale A, Corti D, Draetta GF. Tumors and mitochondrial respiration: a neglected connection. Cancer Res. 2015;75:3685\u20136.","journal-title":"Cancer Res"},{"key":"7638_CR20","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.7150\/ijbs.82217","volume":"19","author":"Y Xia","year":"2023","unstructured":"Xia Y, He C, Hu Z, Wu Z, Hui Y, Liu YY, et al. The mitochondrial protein YME1 Like 1 is important for non-small cell lung cancer cell growth. Int J Biol Sci. 2023;19:1778\u201390.","journal-title":"Int J Biol Sci"},{"key":"7638_CR21","doi-asserted-by":"publisher","first-page":"6163","DOI":"10.7150\/ijbs.78354","volume":"18","author":"JZ Zhang","year":"2022","unstructured":"Zhang JZ, Liu J, Xu YX, Pu WY, Shen MJ, Jiang KQ, et al. Identification of the mitochondrial protein ADCK2 as a therapeutic oncotarget of NSCLC. Int J Biol Sci. 2022;18:6163\u201375.","journal-title":"Int J Biol Sci"},{"key":"7638_CR22","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41419-021-04039-2","volume":"12","author":"T Zhou","year":"2021","unstructured":"Zhou T, Sang YH, Cai S, Xu C, Shi MH. The requirement of mitochondrial RNA polymerase for non-small cell lung cancer cell growth. Cell Death Dis. 2021;12:751.","journal-title":"Cell Death Dis"},{"key":"7638_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40659-019-0214-y","volume":"52","author":"X Liu","year":"2019","unstructured":"Liu X, Jiang Q, Liu H, Luo S. Vitexin induces apoptosis through mitochondrial pathway and PI3K\/Akt\/mTOR signaling in human non-small cell lung cancer A549 cells. Biological Res. 2019;52:7.","journal-title":"Biological Res"},{"key":"7638_CR24","doi-asserted-by":"crossref","unstructured":"Vazquez-Fonseca L, Schafer J, Navas-Enamorado I, Santos-Ocana C, Hernandez-Camacho JD, Guerra I, et al. ADCK2 haploinsufficiency reduces mitochondrial lipid oxidation and causes myopathy associated with CoQ deficiency. J Clin Med. 2019;8:1374.","DOI":"10.3390\/jcm8091374"},{"key":"7638_CR25","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/cdd.2015.94","volume":"23","author":"Y Qi","year":"2016","unstructured":"Qi Y, Liu H, Daniels MP, Zhang G, Xu H. Loss of drosophila i-AAA protease, dYME1L, causes abnormal mitochondria and apoptotic degeneration. Cell Death Differ. 2016;23:291\u2013302.","journal-title":"Cell Death Differ"},{"key":"7638_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.15252\/embr.201438976","volume":"16","author":"TK Rainbolt","year":"2015","unstructured":"Rainbolt TK, Saunders JM, Wiseman RL. YME1L degradation reduces mitochondrial proteolytic capacity during oxidative stress. EMBO Rep. 2015;16:97\u2013106.","journal-title":"EMBO Rep"},{"key":"7638_CR27","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1083\/jcb.201308006","volume":"204","author":"R Anand","year":"2014","unstructured":"Anand R, Wai T, Baker MJ, Kladt N, Schauss AC, Rugarli E, et al. The i-AAA protease YME1L and OMA1 cleave OPA1 to balance mitochondrial fusion and fission. J Cell Biol. 2014;204:919\u201329.","journal-title":"J Cell Biol"},{"key":"7638_CR28","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1091\/mbc.e11-08-0674","volume":"23","author":"L Stiburek","year":"2012","unstructured":"Stiburek L, Cesnekova J, Kostkova O, Fornuskova D, Vinsova K, Wenchich L, et al. YME1L controls the accumulation of respiratory chain subunits and is required for apoptotic resistance, cristae morphogenesis, and cell proliferation. Mol Biol cell. 2012;23:1010\u201323.","journal-title":"Mol Biol cell"},{"key":"7638_CR29","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.bbagrm.2012.04.002","volume":"1819","author":"JJ Arnold","year":"2012","unstructured":"Arnold JJ, Smidansky ED, Moustafa IM, Cameron CE. Human mitochondrial RNA polymerase: structure-function, mechanism and inhibition. Biochim et Biophys Acta. 2012;1819:948\u201360.","journal-title":"Biochim et Biophys Acta"},{"key":"7638_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.molcel.2009.12.021","volume":"37","author":"JM Fuste","year":"2010","unstructured":"Fuste JM, Wanrooij S, Jemt E, Granycome CE, Cluett TJ, Shi Y, et al. Mitochondrial RNA polymerase is needed for activation of the origin of light-strand DNA replication. Mol cell. 2010;37:67\u201378.","journal-title":"Mol cell"},{"key":"7638_CR31","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.1038\/sj.emboj.7600465","volume":"23","author":"M Gaspari","year":"2004","unstructured":"Gaspari M, Falkenberg M, Larsson NG, Gustafsson CM. The mitochondrial RNA polymerase contributes critically to promoter specificity in mammalian cells. EMBO J. 2004;23:4606\u201314.","journal-title":"EMBO J"},{"key":"7638_CR32","doi-asserted-by":"crossref","unstructured":"Wang S, Kang Y, Wang R, Deng J, Yu Y, Yu J, et al. Emerging roles of NDUFS8 located in mitochondrial complex I in different diseases. Molecules. 2022;27:8754.","DOI":"10.3390\/molecules27248754"},{"key":"7638_CR33","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0167-4781(97)00020-1","volume":"1351","author":"V Procaccio","year":"1997","unstructured":"Procaccio V, Depetris D, Soularue P, Mattei MG, Lunardi J, Issartel JP. cDNA sequence and chromosomal localization of the NDUFS8 human gene coding for the 23 kDa subunit of the mitochondrial complex I. Biochim et Biophys Acta. 1997;1351:37\u201341.","journal-title":"Biochim et Biophys Acta"},{"key":"7638_CR34","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/s41419-022-05049-4","volume":"13","author":"Y Xue","year":"2022","unstructured":"Xue Y, Jiang K, Ou L, Shen M, Yang Y, Lu J, et al. Targeting sphingosine kinase 1\/2 by a novel dual inhibitor SKI-349 suppresses non-small cell lung cancer cell growth. Cell Death Dis. 2022;13:602.","journal-title":"Cell Death Dis"},{"key":"7638_CR35","doi-asserted-by":"publisher","first-page":"756148","DOI":"10.3389\/fonc.2021.756148","volume":"11","author":"PF Jiao","year":"2021","unstructured":"Jiao PF, Tang PJ, Chu D, Li YM, Xu WH, Ren GF. Long Non-Coding RNA THOR depletion inhibits human non-small cell lung cancer cell growth. Front Oncol. 2021;11:756148.","journal-title":"Front Oncol"},{"key":"7638_CR36","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41597-023-02074-6","volume":"10","author":"KH Prazanowska","year":"2023","unstructured":"Prazanowska KH, Lim SB. An integrated single-cell transcriptomic dataset for non-small cell lung cancer. Sci Data. 2023;10:167.","journal-title":"Sci Data"},{"key":"7638_CR37","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1038\/s41467-020-16164-1","volume":"11","author":"N Kim","year":"2020","unstructured":"Kim N, Kim HK, Lee K, Hong Y, Cho JH, Choi JW, et al. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. Nat Commun. 2020;11:2285.","journal-title":"Nat Commun"},{"key":"7638_CR38","doi-asserted-by":"publisher","first-page":"4894","DOI":"10.7150\/thno.56383","volume":"11","author":"JY Bai","year":"2021","unstructured":"Bai JY, Li Y, Xue GH, Li KR, Zheng YF, Zhang ZQ, et al. Requirement of Galphai1 and Galphai3 in interleukin-4-induced signaling, macrophage M2 polarization and allergic asthma response. Theranostics. 2021;11:4894\u2013909.","journal-title":"Theranostics"},{"key":"7638_CR39","doi-asserted-by":"publisher","first-page":"5667","DOI":"10.7150\/ijbs.77126","volume":"18","author":"J Zhang","year":"2022","unstructured":"Zhang J, Yin DP, Zhang Y, Zhang JN, Yang Y, Zhang ZQ, et al. Identification of Galphai3 as a novel molecular therapeutic target of cervical cancer. Int J Biol Sci. 2022;18:5667\u201380.","journal-title":"Int J Biol Sci"},{"key":"7638_CR40","doi-asserted-by":"publisher","first-page":"8535","DOI":"10.7150\/thno.61452","volume":"11","author":"Y Wang","year":"2021","unstructured":"Wang Y, Liu YY, Chen MB, Cheng KW, Qi LN, Zhang ZQ, et al. Neuronal-driven glioma growth requires Galphai1 and Galphai3. Theranostics. 2021;11:8535\u201349.","journal-title":"Theranostics"},{"key":"7638_CR41","doi-asserted-by":"publisher","first-page":"7586","DOI":"10.7150\/thno.78616","volume":"12","author":"YZ Guo","year":"2022","unstructured":"Guo YZ, Chen G, Huang M, Wang Y, Liu YY, Jiang Q, et al. TIMM44 is a potential therapeutic target of human glioma. Theranostics. 2022;12:7586\u2013602.","journal-title":"Theranostics"},{"key":"7638_CR42","first-page":"223","volume":"14","author":"F Liu","year":"2023","unstructured":"Liu F, Chen G, Zhou LN, Wang Y, Zhang ZQ, Qin X, et al. YME1L overexpression exerts pro-tumorigenic activity in glioma by promoting Galphai1 expression and Akt activation. Protein Cell. 2023;14:223\u20139.","journal-title":"Protein Cell"},{"key":"7638_CR43","first-page":"217","volume":"14","author":"G Xu","year":"2023","unstructured":"Xu G, Qi LN, Zhang MQ, Li XY, Chai JL, Zhang ZQ, et al. Galphai1\/3 mediation of Akt-mTOR activation is important for RSPO3-induced angiogenesis. Protein cell. 2023;14:217\u201322.","journal-title":"Protein cell"},{"key":"7638_CR44","doi-asserted-by":"publisher","first-page":"e47258","DOI":"10.1371\/journal.pone.0047258","volume":"7","author":"JS You","year":"2012","unstructured":"You JS, Frey JW, Hornberger TA. Mechanical stimulation induces mTOR signaling via an ERK-independent mechanism: implications for a direct activation of mTOR by phosphatidic acid. PloS ONE. 2012;7:e47258.","journal-title":"PloS ONE"},{"key":"7638_CR45","doi-asserted-by":"publisher","first-page":"669518","DOI":"10.3389\/fonc.2021.669518","volume":"11","author":"JH Zha","year":"2021","unstructured":"Zha JH, Xia YC, Ye CL, Hu Z, Zhang Q, Xiao H, et al. The anti-non-small cell lung cancer cell activity by a mTOR kinase inhibitor PQR620. Front Oncol. 2021;11:669518.","journal-title":"Front Oncol"},{"key":"7638_CR46","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1172\/JCI20683","volume":"114","author":"DM Kirby","year":"2004","unstructured":"Kirby DM, Salemi R, Sugiana C, Ohtake A, Parry L, Bell KM, et al. NDUFS6 mutations are a novel cause of lethal neonatal mitochondrial complex I deficiency. J Clin Investig. 2004;114:837\u201345.","journal-title":"J Clin Investig"},{"key":"7638_CR47","doi-asserted-by":"crossref","unstructured":"Liu F, Chen G, Zhou L-N, Wang Y, Zhang Z-q, Qin X, et al. YME1L overexpression exerts pro-tumorigenic activity in glioma by promoting G\u03b1i1 expression and Akt activation. Protein Cell. 2022;14:223\u2013229.","DOI":"10.1093\/procel\/pwac011"},{"key":"7638_CR48","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41419-021-03655-2","volume":"12","author":"YC Xia","year":"2021","unstructured":"Xia YC, Zha JH, Sang YH, Yin H, Xu GQ, Zhen J, et al. AMPK activation by ASP4132 inhibits non-small cell lung cancer cell growth. Cell Death Dis. 2021;12:365.","journal-title":"Cell Death Dis"},{"key":"7638_CR49","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/01926230701320337","volume":"35","author":"S Elmore","year":"2007","unstructured":"Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495\u2013516.","journal-title":"Toxicol Pathol"},{"key":"7638_CR50","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nature25023","volume":"552","author":"H Yang","year":"2017","unstructured":"Yang H, Jiang X, Li B, Yang HJ, Miller M, Yang A, et al. Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40. Nature. 2017;552:368\u201373.","journal-title":"Nature"},{"key":"7638_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BJ20110892","volume":"441","author":"B Magnuson","year":"2012","unstructured":"Magnuson B, Ekim B, Fingar DC. Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem J. 2012;441:1\u201321.","journal-title":"Biochem J"},{"key":"7638_CR52","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","volume":"110","author":"DH Kim","year":"2002","unstructured":"Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 2002;110:163\u201375.","journal-title":"Cell"},{"key":"7638_CR53","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1124\/mol.108.047985","volume":"75","author":"LF Hu","year":"2009","unstructured":"Hu LF, Lu M, Wu ZY, Wong PT, Bian JS. Hydrogen sulfide inhibits rotenone-induced apoptosis via preservation of mitochondrial function. Mol Pharmacol. 2009;75:27\u201334.","journal-title":"Mol Pharmacol"},{"key":"7638_CR54","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/j.chembiol.2011.08.009","volume":"18","author":"X Ma","year":"2011","unstructured":"Ma X, Jin M, Cai Y, Xia H, Long K, Liu J, et al. Mitochondrial electron transport chain complex III is required for antimycin A to inhibit autophagy. Chem Biol. 2011;18:1474\u201381.","journal-title":"Chem Biol"},{"key":"7638_CR55","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/resp.13870","volume":"25","author":"SK Vinod","year":"2020","unstructured":"Vinod SK, Hau E. Radiotherapy treatment for lung cancer: current status and future directions. Respirology. 2020;25:61\u201371.","journal-title":"Respirology"},{"key":"7638_CR56","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/14737140.2020.1760094","volume":"20","author":"N Giaj-Levra","year":"2020","unstructured":"Giaj-Levra N, Borghetti P, Bruni A, Ciammella P, Cuccia F, Fozza A, et al. Current radiotherapy techniques in NSCLC: challenges and potential solutions. Expert Rev Anticancer Ther. 2020;20:387\u2013402.","journal-title":"Expert Rev Anticancer Ther"},{"key":"7638_CR57","doi-asserted-by":"publisher","first-page":"103194","DOI":"10.1016\/j.critrevonc.2020.103194","volume":"157","author":"EN Imyanitov","year":"2021","unstructured":"Imyanitov EN, Iyevleva AG, Levchenko EV. Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives. Critic Rev Oncol\/Hematol. 2021;157:103194.","journal-title":"Critic Rev Oncol\/Hematol"},{"key":"7638_CR58","doi-asserted-by":"publisher","first-page":"31357","DOI":"10.1038\/srep31357","volume":"6","author":"CY Su","year":"2016","unstructured":"Su CY, Chang YC, Yang CJ, Huang MS, Hsiao M. The opposite prognostic effect of NDUFS1 and NDUFS8 in lung cancer reflects the oncojanus role of mitochondrial complex I. Sci Rep. 2016;6:31357.","journal-title":"Sci Rep"},{"key":"7638_CR59","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/1759-7714.13328","volume":"11","author":"AC Tan","year":"2020","unstructured":"Tan AC. Targeting the PI3K\/Akt\/mTOR pathway in non-small cell lung cancer (NSCLC). Thoracic Cancer. 2020;11:511\u20138.","journal-title":"Thoracic Cancer"},{"key":"7638_CR60","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.2217\/pgs.15.122","volume":"16","author":"C Perez-Ramirez","year":"2015","unstructured":"Perez-Ramirez C, Canadas-Garre M, Molina MA, Faus-Dader MJ, Calleja-Hernandez MA. PTEN and PI3K\/AKT in non-small-cell lung cancer. Pharmacogenomics. 2015;16:1843\u201362.","journal-title":"Pharmacogenomics"},{"key":"7638_CR61","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.bcp.2014.05.011","volume":"90","author":"C Fumarola","year":"2014","unstructured":"Fumarola C, Bonelli MA, Petronini PG, Alfieri RR. Targeting PI3K\/AKT\/mTOR pathway in non small cell lung cancer. Biochem Pharmacol. 2014;90:197\u2013207.","journal-title":"Biochem Pharmacol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07638-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07638-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07638-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T05:02:21Z","timestamp":1745211741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07638-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7638"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07638-5","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]},"assertion":[{"value":"29 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. Human tissues and primary human cells were provided by the participants with written-informed consent. The management of these human tissue samples and cells followed protocols sanctioned by the Soochow University Ethics Committee, aligning with the Declaration of Helsinki standards. All animal procedures were approved by the Institutional Animal Care and Use Committee of Soochow University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"321"}}